Q&A: Understanding the relationship between lymphoma, eczema and dupilumab

The dermatology community has long debated whether dupilumab treatment for atopic dermatitis is associated with the development of cutaneous T-cell lymphoma — a concern that becomes more urgent when children are involved. In 2024, a retrospective cohort study suggested that dupilumab (Dupixent; Sanofi, Regeneron) was associated with an increased risk for cutaneous T-cell lymphoma in